Xavier Rossello
Overview
Explore the profile of Xavier Rossello including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
165
Citations
2999
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Byrne R, Valgimigli M, Bhatt D, Coughlan J, Gibson C, Rossello X, et al.
Eur Heart J
. 2025 Mar;
PMID: 40056109
No abstract available.
2.
Rossello X, Gonzalez-Del-Hoyo M, Aktaa S, Gale C, Barbash I, Claeys M, et al.
Eur Heart J Acute Cardiovasc Care
. 2025 Jan;
PMID: 39874263
Background: Closing the evidence-practice gap for the treatment of acute coronary syndrome (ACS) is central to improving quality of care. Under the European Society of Cardiology (ESC) framework, we aimed...
3.
Petrie M, Udell J, Anker S, Harrington J, Jones W, Mattheus M, et al.
Eur J Heart Fail
. 2024 Dec;
PMID: 39725521
Aims: In the EMPACT-MI trial, empagliflozin reduced heart failure (HF) hospitalizations but not mortality in acute myocardial infarction (MI). Contemporary reports of clinical event rates with and without type 2...
4.
Vrints C, Andreotti F, Koskinas K, Rossello X, Adamo M, Ainslie J, et al.
G Ital Cardiol (Rome)
. 2024 Nov;
25(12 Suppl 1):e1-e132.
PMID: 39611224
No abstract available.
5.
Herrington W, Staplin N, Agrawal N, Wanner C, Green J, Hauske S, et al.
N Engl J Med
. 2024 Oct;
392(8):777-787.
PMID: 39453837
Background: In the EMPA-KIDNEY trial, empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, had positive cardiorenal effects in patients with chronic kidney disease who were at risk for disease progression. Post-trial...
6.
Haro A, Jacob J, Rossello X, Llorens P, Herrero P, Alquezar-Arbe A, et al.
Int J Cardiol
. 2024 Oct;
418:132615.
PMID: 39393442
Objectives: The aim of the present study was to evaluate the impact of chronic treatment with angiotensin-converting enzyme inhibitors (ACEI) or angiotensin receptor blockers (ARB) on short-term clinical outcomes after...
7.
Taylor D, Skoza W, Rossello X
Eur Heart J Acute Cardiovasc Care
. 2024 Sep;
13(10):745-746.
PMID: 39315629
No abstract available.
8.
Moreno-Arciniegas A, Garcia A, Kelm M, DAmore F, Gomes Da Silva M, Sanchez-Gonzalez J, et al.
Eur J Heart Fail
. 2024 Aug;
26(10):2213-2222.
PMID: 39212445
Aims: There is a lack of therapies able to prevent anthracycline cardiotoxicity (AC). Remote ischaemic conditioning (RIC) has shown beneficial effects in preclinical models of AC. Methods: REmote iSchemic condItioning...
9.
Vrints C, Andreotti F, Koskinas K, Rossello X, Adamo M, Ainslie J, et al.
Eur Heart J
. 2024 Aug;
45(36):3415-3537.
PMID: 39210710
No abstract available.
10.
Rossello X, Caimari F
Lancet Diabetes Endocrinol
. 2024 Aug;
12(9):605-606.
PMID: 39098316
No abstract available.